Vandetanib

Drug #2275

Vandetanib is an antineoplastic agent. It is a protein kinase inhibitor which inhibits the VEGFR-2, EGFR and RET tyrosine kinase. It is indicated in the treatment of medullary thyroid cancer.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin.

It belongs to Protein kinase inhibitor pharmacological group on the basis of mechanism of action.

Non-proprietary name: Vandetanib.

Pharmacokinetics

Distribution: Vandetanib has a volume of distribution is 7450 L. plasma protein binding is 93.7%.

Elimination: it is metabolised via hepatic, plasma half-life is 19 days, renal excretion is 25%, 44% in feces.

Indications

Vandetanib is primarily indicated in conditions like Thyroid cancer.

Vandetanib is also indicated for secondary conditions like Tumor induced angiogenesis.

Contraindications

Vandetanib is contraindicated in conditions like Renal impairment, Hepatic impairment, Hypersensitivity, Lactation, QTc prolongation.

Dosage

Vandetanib's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
300 mg	300 mg	Every 24h	PO	Take with or without food at about the same time each day. Starting dose is 200 mg in patients with renal impairment.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

5 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

The signs and symptoms that are produced after acute overdosage of Vandetanib are Diarrhea, Hypertension, QT prolongation, Rashes .

Vandetanib is known to cause more or less tolerable side effects which are usually transient. These include Blurred vision, Diarrhea, Hypertension , Nausea, QT prolongation, Rashes .

Warnings / Precautions

Vandetanib should not be started in patients with QTc prolongation and in patients with a history of torsade de points unless corrected. Monitor ECG and blood tests during treatment. Maintain a normal range of serum electrolytes to reduce the risk of QTc prolongation. It should not be used in patients with posterior reversible encephalopathy syndrome. This syndrome should be considered in patients with seizures, headache, visual disturbances, confusion or altered mental function. Discontinue the drug if Steven Johnsons syndrome or severe diarrhea occur. Wear protective clothing and use sunscreen to prevent phototoxicity. Use with caution in patients with brain metastases, heart failure, hypertension, renal and hepatic impairment, ALT elevation or interstitial disease.

Available Brands

None recorded.

Storage Conditions

Vandetanib should be stored Tab.